Core Viewpoint - Hansen Pharmaceutical (002412) stated on September 26 that the company's operational data and other information will be disclosed in accordance with information disclosure rules in periodic reports, and specific details can be found in the company's announcements [1] Group 1 - The company engages with investors through an interactive platform to address inquiries [1] - The company emphasizes adherence to information disclosure regulations [1] - The company encourages stakeholders to refer to official announcements for detailed information [1]

Core Viewpoint - Hansen Pharmaceutical (002412) is currently in the process of scaling up the production technology for its new traditional Chinese medicine product, Cangrong Granules, which is in the pilot study phase [1] Group 1 - The company is actively engaged in product research and development [1] - Cangrong Granules is a new drug derived from traditional Chinese medicine [1] - The product is currently undergoing process pilot testing [1]

Group 1 - The company has been asked about the proportion of innovative drugs in its R&D plans for the year [2] - The company stated that its traditional Chinese medicine new drug, Cangrong Granules, is currently in the process of pilot-scale research [2] - Further details regarding the company's R&D plans will be available in the 2024 annual report [2]

Group 1 - The core viewpoint of the article is that Hansen Pharmaceutical (002412) acknowledges that the fluctuations in its stock price in the secondary market are influenced by multiple factors, including macro policies, market trends, and investor preferences [1] - The company's management is committed to promoting the company's development and creating value for investors [1]

Core Viewpoint - The performance briefing held by Hunan Hansen Pharmaceutical Co., Ltd. focused on two main issues: the financial loss from investing in Sanxiang Bank and potential acquisition plans for Kangpu Pharmaceutical [1] Group 1: Financial Performance and Strategic Investments - The company acknowledged financial losses due to its investment in Sanxiang Bank, which is part of its "one body, two wings" development strategy aimed at maintaining its core traditional Chinese medicine business while expanding into the health industry and integrating financial services [1] - The company committed to timely information disclosure regarding any significant matters related to the transfer of its stake in Sanxiang Bank [1] Group 2: Potential Mergers and Acquisitions - Investors inquired about the possibility of acquiring Kangpu Pharmaceutical, in which the controlling shareholder Liu Ling'an increased his stake in 2021 [1] - The company stated that it would also disclose any future merger and acquisition activities in a timely manner [1] Group 3: Investor Communication - The performance briefing allowed direct communication between investors and the company's management, highlighting the company's commitment to transparency and timely information disclosure regarding strategic investments and potential acquisitions [1]

Group 1: Company Strategy - The company's main business is traditional Chinese medicine, and it has invested in Sanxiang Bank, which has led to financial losses. The company emphasizes that the investment is part of its "one body, two wings" development strategy, integrating traditional medicine with the health and financial industries [2]. - The company will disclose any significant matters related to the transfer of Sanxiang Bank's equity in a timely manner [2]. Group 2: Future Plans - There is a question regarding whether the company has plans to acquire Kangpu Pharmaceutical after the major shareholder Liu Ling'an increased his stake in 2021. The company stated that any future acquisition matters will also be disclosed promptly [2].

Group 1 - The company Hansen Pharmaceutical (002412) reported that as of August 29, 2025, the total number of shareholders, including those with credit accounts, is 23,580 [1]

Group 1 - The company, Hunan Hansen Pharmaceutical Co., Ltd., will participate in the "2025 Hunan Listed Companies Investor Online Collective Reception Day and Semi-Annual Performance Briefing" event [1] - The event is organized by the China Securities Regulatory Commission Hunan Regulatory Bureau, Hunan Listed Companies Association, and Shenzhen Panorama Network Co., Ltd. [1] - The online event will take place on September 19, 2025, from 14:00 to 17:00, allowing investors to engage through various platforms [1] Group 2 - The company's board secretary and securities affairs representative will interact with investors through an online Q&A format [1] - Investors are encouraged to actively participate in the event [1]

证券代码：002412 证券简称：汉森制药 公告编号：2025-019 湖南汉森制药股份有限公司 湖南汉森制药股份有限公司 董事会 2025 年 9 月 12 日 关于参加 2025 年湖南辖区上市公司投资者网上集体接待日 暨半年度业绩说明会活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或者重大遗漏。 为进一步加强与广大投资者的互动交流，湖南汉森制药股份有限公司（以下 简称"公司"）将参加由中国证券监督管理委员会湖南监管局、湖南省上市公司 协会与深圳市全景网络有限公司联合举办的"资本聚三湘 楚光耀新程—— 2025 年湖南辖区上市公司投资者网上集体接待日暨半年度业绩说明会"活动， 现将有关事项公告如下： 本次活动将采取网络远程的方式举行，投资者可以登录"全景路演"网站 （http://rs.p5w.net），或关注微信公众号：全景财经，或下载"全景路演"APP， 参与本次互动交流，活动时间为 2025 年 9 月 19 日(星期五)14:00-17:00。届时 公司董事会秘书、证券事务代表将通过网络在线问答互动的形式，就投资者关心 的问题进行沟通与交流，欢迎广 ...

Core Viewpoint - Hansen Pharmaceutical has commenced the production and sale of 10mg empagliflozin tablets, which are indicated for the treatment of type 2 diabetes and symptomatic chronic heart failure in adults, aimed at reducing the risk of hospitalization due to heart failure. The impact of this product on the company's performance in the second half of the year remains uncertain [1] Group 1 - The 10mg empagliflozin tablets are now available for sale [1] - The product is intended for two specific medical conditions: type 2 diabetes and symptomatic chronic heart failure [1] - The company has not provided clarity on how this product will affect its financial performance in the latter half of the year [1]